Turning Point Therapeutics Inc

TPTX NASDAQ
42.42
+0.01
+0.02%
Closed 16:25 08/16 EDT
Open
42.83
Prev Close
42.41
High
45.19
Low
40.69
Volume
147.72K
Avg Vol (3M)
169.55K
52 Week High
47.72
52 Week Low
24.21
% Turnover
0.72%
Market Cap
865.57M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Turning Point Therapeutics Inc TPTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
MORE >

Recently

Name
Price
%Change